47N0 Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of critical care products. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Citius Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.29 |
| 52 Week High | US$20.64 |
| 52 Week Low | US$3.00 |
| Beta | 1.29 |
| 1 Month Change | 0% |
| 3 Month Change | -30.07% |
| 1 Year Change | -78.58% |
| 3 Year Change | -91.05% |
| 5 Year Change | -80.93% |
| Change since IPO | -85.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| 47N0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.7% | 2.7% |
| 1Y | -78.6% | -15.9% | 17.0% |
Return vs Industry: 47N0 underperformed the German Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: 47N0 underperformed the German Market which returned 17% over the past year.
Price Volatility
| 47N0 volatility | |
|---|---|
| 47N0 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 47N0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 47N0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 23 | Leonard Mazur | citiuspharma.com |
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
Citius Pharmaceuticals, Inc. Fundamentals Summary
| 47N0 fundamental statistics | |
|---|---|
| Market cap | €22.03m |
| Earnings (TTM) | -€38.30m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs 47N0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 47N0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$0 |
| Earnings | US$0 |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.68 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 47N0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/15 18:13 |
| End of Day Share Price | 2024/11/25 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Citius Pharmaceuticals, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Jason Kolbert | H.C. Wainwright & Co. |
| Vernon Bernardino | H.C. Wainwright & Co. |